Cargando…

Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity

To examine the effects of formononetin (FMN) on Acetaminophen (APAP)-induced liver injury in vitro and in vivo. Human non-tumor hepatic cells LO2 were pretreated with either vehicle or FMN (20, 40 μM), for 6 h, followed by incubation with or without APAP (10 mM) for 24 h. In an in vivo assay, male B...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Fen, Wan, Chunpeng, Li, Weifang, Yao, Liangliang, Zhao, Hongqian, Zou, Yuan, Peng, Dewei, Huang, Weifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325199/
https://www.ncbi.nlm.nih.gov/pubmed/28234915
http://dx.doi.org/10.1371/journal.pone.0170900
_version_ 1782510333584211968
author Jin, Fen
Wan, Chunpeng
Li, Weifang
Yao, Liangliang
Zhao, Hongqian
Zou, Yuan
Peng, Dewei
Huang, Weifeng
author_facet Jin, Fen
Wan, Chunpeng
Li, Weifang
Yao, Liangliang
Zhao, Hongqian
Zou, Yuan
Peng, Dewei
Huang, Weifeng
author_sort Jin, Fen
collection PubMed
description To examine the effects of formononetin (FMN) on Acetaminophen (APAP)-induced liver injury in vitro and in vivo. Human non-tumor hepatic cells LO2 were pretreated with either vehicle or FMN (20, 40 μM), for 6 h, followed by incubation with or without APAP (10 mM) for 24 h. In an in vivo assay, male BALB/c mice were randomly divided into four groups: (1) control group; (2) APAP group; (3) APAP + FMN (50 mg/Kg); (4) APAP + FMN (100 mg/Kg). The mice in the control and APAP groups were pre-treated with vehicle; the other two groups were pretreated daily with FMN (50, 100 mg/Kg) orally for 7 consecutive days. After the final treatment, acute liver injury was induced in all groups, except the control group, by intraperitoneal (i.p.) injection of 300 mg/Kg APAP. In LO2 cells, APAP exposure decreased the cell viability and glutathione (GSH) content, which were both greatly restored by FMN pretreatment. Overdose of APAP increased hepatic malondialdehyde (MDA) content, serum alanine aminotransferase (ALT), and aspartate aminotransferase (AST) activity in experimental mice. Supplementation with 100 mg/Kg FMN significantly reduced APAP-induced elevated levels of MDA (1.97 ± 0.27 vs 0.55 ± 0.14 nmol/mg protein, p < 0.001), ALT (955.80 ± 209.40 vs 46.90 ± 20.40 IU/L, p < 0.001) and AST (1533.80 ± 244.80 vs 56.70 ± 28.80 IU/L, p < 0.001), and hepatic GSH level (5.54 ± 0.93 vs 8.91 ± 1.11 μmol/mg protein, p < 0.001) was significantly increased. These results were further validated by histopathology and TdT-mediated biotin-dUTP nick-endlabeling (TUNEL) staining, pretreatment with 100 mg/Kg FMN significant decreased APAP-induced hepatocellular damage and cell apoptosis (36.55 ± 3.82 vs 2.58 ± 1.80%, p < 0.001). Concomitantly, FMN stimulated the expression of Nrf2 and antioxidant gene expression in the presence of APAP. These data provide an experimental basis for the use of FMN in the treatment of patients with APAP-induced hepatotoxicity.
format Online
Article
Text
id pubmed-5325199
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53251992017-03-09 Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity Jin, Fen Wan, Chunpeng Li, Weifang Yao, Liangliang Zhao, Hongqian Zou, Yuan Peng, Dewei Huang, Weifeng PLoS One Research Article To examine the effects of formononetin (FMN) on Acetaminophen (APAP)-induced liver injury in vitro and in vivo. Human non-tumor hepatic cells LO2 were pretreated with either vehicle or FMN (20, 40 μM), for 6 h, followed by incubation with or without APAP (10 mM) for 24 h. In an in vivo assay, male BALB/c mice were randomly divided into four groups: (1) control group; (2) APAP group; (3) APAP + FMN (50 mg/Kg); (4) APAP + FMN (100 mg/Kg). The mice in the control and APAP groups were pre-treated with vehicle; the other two groups were pretreated daily with FMN (50, 100 mg/Kg) orally for 7 consecutive days. After the final treatment, acute liver injury was induced in all groups, except the control group, by intraperitoneal (i.p.) injection of 300 mg/Kg APAP. In LO2 cells, APAP exposure decreased the cell viability and glutathione (GSH) content, which were both greatly restored by FMN pretreatment. Overdose of APAP increased hepatic malondialdehyde (MDA) content, serum alanine aminotransferase (ALT), and aspartate aminotransferase (AST) activity in experimental mice. Supplementation with 100 mg/Kg FMN significantly reduced APAP-induced elevated levels of MDA (1.97 ± 0.27 vs 0.55 ± 0.14 nmol/mg protein, p < 0.001), ALT (955.80 ± 209.40 vs 46.90 ± 20.40 IU/L, p < 0.001) and AST (1533.80 ± 244.80 vs 56.70 ± 28.80 IU/L, p < 0.001), and hepatic GSH level (5.54 ± 0.93 vs 8.91 ± 1.11 μmol/mg protein, p < 0.001) was significantly increased. These results were further validated by histopathology and TdT-mediated biotin-dUTP nick-endlabeling (TUNEL) staining, pretreatment with 100 mg/Kg FMN significant decreased APAP-induced hepatocellular damage and cell apoptosis (36.55 ± 3.82 vs 2.58 ± 1.80%, p < 0.001). Concomitantly, FMN stimulated the expression of Nrf2 and antioxidant gene expression in the presence of APAP. These data provide an experimental basis for the use of FMN in the treatment of patients with APAP-induced hepatotoxicity. Public Library of Science 2017-02-24 /pmc/articles/PMC5325199/ /pubmed/28234915 http://dx.doi.org/10.1371/journal.pone.0170900 Text en © 2017 Jin et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Jin, Fen
Wan, Chunpeng
Li, Weifang
Yao, Liangliang
Zhao, Hongqian
Zou, Yuan
Peng, Dewei
Huang, Weifeng
Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity
title Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity
title_full Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity
title_fullStr Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity
title_full_unstemmed Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity
title_short Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity
title_sort formononetin protects against acetaminophen-induced hepatotoxicity through enhanced nrf2 activity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325199/
https://www.ncbi.nlm.nih.gov/pubmed/28234915
http://dx.doi.org/10.1371/journal.pone.0170900
work_keys_str_mv AT jinfen formononetinprotectsagainstacetaminopheninducedhepatotoxicitythroughenhancednrf2activity
AT wanchunpeng formononetinprotectsagainstacetaminopheninducedhepatotoxicitythroughenhancednrf2activity
AT liweifang formononetinprotectsagainstacetaminopheninducedhepatotoxicitythroughenhancednrf2activity
AT yaoliangliang formononetinprotectsagainstacetaminopheninducedhepatotoxicitythroughenhancednrf2activity
AT zhaohongqian formononetinprotectsagainstacetaminopheninducedhepatotoxicitythroughenhancednrf2activity
AT zouyuan formononetinprotectsagainstacetaminopheninducedhepatotoxicitythroughenhancednrf2activity
AT pengdewei formononetinprotectsagainstacetaminopheninducedhepatotoxicitythroughenhancednrf2activity
AT huangweifeng formononetinprotectsagainstacetaminopheninducedhepatotoxicitythroughenhancednrf2activity